{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:35:18Z","timestamp":1790883318008,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cgh.2021.06.028","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T05:06:44Z","timestamp":1624943204000},"page":"1039-1047.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3257-3271","authenticated-orcid":false,"given":"Isabelle","family":"Mack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schwille-Kiuntke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazar","family":"Mazurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Niesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"M\u00f6nnikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Enck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.06.028_bib1","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cgh.2021.06.028_bib2","doi-asserted-by":"crossref","first-page":"e13473","DOI":"10.1111\/nmo.13473","article-title":"Not more, but less studies are warranted if you take your meta-analysis seriously","volume":"31","author":"Enck","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2021.06.028_bib3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.06.028_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.gastro.2020.05.060","article-title":"AGA technical review on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Preidis","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.06.028_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.06.028_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12263-011-0218-x","article-title":"The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept)","volume":"6","author":"Taverniti","year":"2011","journal-title":"Genes Nutr"},{"key":"10.1016\/j.cgh.2021.06.028_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","article-title":"Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"5","author":"Andresen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.06.028_bib8","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3390\/ijms20102534","article-title":"Health benefits of heat-killed (tyndallized) probiotics: an overview","volume":"20","author":"Pique","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cgh.2021.06.028_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2982.2008.01156.x","article-title":"A\u00a0mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome: a randomized controlled trial with primary care physicians","volume":"20","author":"Enck","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2021.06.028_bib10","series-title":"European Medicinal Agency","article-title":"Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome","year":"2014"},{"key":"10.1016\/j.cgh.2021.06.028_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004836-199407000-00008","article-title":"An office guide to whole-gut transit time: patients\u2019 recollection of their stool form","volume":"19","author":"Heaton","year":"1994","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2021.06.028_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.06.028_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ajg.2009.13","article-title":"Adequate relief in a treatment trial with IBS patients: a prospective assessment","volume":"104","author":"Passos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.06.028_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1023\/A:1024159226274","article-title":"Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy","volume":"48","author":"Gordon","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.06.028_bib15","first-page":"109","article-title":"The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders","volume":"11","author":"Farrar","year":"2010","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.cgh.2021.06.028_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2021.06.028_bib17","series-title":"U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, eds","article-title":"Guidance for industry irritable bowel syndrome: clinical evaluation of drugs for treatment","year":"2012"},{"key":"10.1016\/j.cgh.2021.06.028_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gutjnl-2014-308188","article-title":"Randomised controlled trial of mesalazine in IBS","volume":"65","author":"Barbara","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.06.028_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.06.028_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling fhe false discover rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society Series B (Methodological)"},{"key":"10.1016\/j.cgh.2021.06.028_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2468-1253(20)30243-0","article-title":"Paraprobiotics for irritable bowel syndrome: all that glitters is not gold","volume":"5","author":"Enck","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.06.028_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fphar.2020.00332","article-title":"Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2021.06.028_bib23","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1053\/j.gastro.2003.10.011","article-title":"Choosing outcome variables: global assessment and diaries","volume":"126","author":"Naliboff","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.06.028_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/2050640615603009","article-title":"Prevalence of constipation in the German population: a representative survey (GECCO)","volume":"4","author":"Enck","year":"2016","journal-title":"United European Gastroenterol J"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521006923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521006923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:08Z","timestamp":1761543368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521006923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1542356521006923"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.06.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}